Search for content, post, videos
Advertisement

TikoMed collaborates with Oslo University Hospital

The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have officially signed a research collaboration agreement.

Common ambition for the parties is for their collaboration to lead to more knowledge and better treatment options for patients diagnosed with Amyotrophic Lateral Sclerosis – ALS. TikoMed has previously completed and reported on two successful phase 2a clinical studies in ALS, one at the Sahlgrenska University Hospital in Sweden and one at the University of Birmingham in the UK, both with promising results. The trial data establish the safety and tolerability of ILB in people with ALS, while also indicating its future potential to be the first disease-modifying drug to treat both familial and sporadic ALS with minimal side-effects.

“We are very excited about the clinical potential for ILB, which may prove to be a game changing treatment for many devastating neuro-degenerative diseases,” says TikoMed’s Scientific Advisor, Professor Ann Logan, Honorary Professor of Regenerative Medicine at the University of Warwick.

Advertisement

Photo: iStock

Advertisement